Grace Therapeutics (GRCE)
NASDAQ:GRCE
Want to see GRCE full AI Analyst Report?
Top Page
Grace Therapeutics
(NASDAQ:GRCE)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▼(-56.52% Downside)
Action:ReiteratedDate:04/28/26
The score is primarily held back by pre-revenue financials with ongoing losses and cash burn, alongside a weak technical trend with the stock far below major moving averages. Offsetting these are a debt-free balance sheet and corporate updates indicating clinical support for GTx-104 and a non-clinical/CMC-focused CRL that outlines a remediation pathway, though with meaningful timing risk.
Positive Factors
Clinical Proof-of-Concept
A Phase 3 trial meeting its primary endpoint establishes durable clinical proof-of-concept versus oral nimodipine. With the FDA not citing clinical concerns, the program’s clinical risk is materially lower, improving long-term prospects for approval and commercial adoption once CMC/nonclinical issues are remediated.
Negative Factors
Persistent Cash Burn
Ongoing negative operating and free cash flow indicates the company cannot self-fund development. Over a multi-month horizon this heightens dependence on external financing, increasing dilution risk and constraining strategic options if capital markets tighten or remediation timelines lengthen.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Proof-of-Concept
A Phase 3 trial meeting its primary endpoint establishes durable clinical proof-of-concept versus oral nimodipine. With the FDA not citing clinical concerns, the program’s clinical risk is materially lower, improving long-term prospects for approval and commercial adoption once CMC/nonclinical issues are remediated.
Read all positive factors
Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.50M
Dividend YieldN/A
Average Volume (3M)58.56K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue GrowthN/A
EPS Growth70.83%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding15,474,026
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.36K
Enterprise Value/Ebitda-1.78
Forecast
1Y Price Target
$6.00Price Target Upside30.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$8.55M
Grace Therapeutics Business Overview & Revenue Model
Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrh...
How the Company Makes Money
null...
Grace Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 196.00K |
| Gross Profit | -4.12K | 0.00 | -11.00K | 0.00 | 0.00 | 120.00K |
| EBITDA | -7.76M | -16.67M | -14.62M | -18.12M | -15.34M | -9.79M |
| Net Income | -6.84M | -9.57M | -12.85M | -42.43M | -9.82M | -19.68M |
Balance Sheet | ||||||
| Total Assets | 68.49M | 71.99M | 73.30M | 79.12M | 128.62M | 62.46M |
| Cash, Cash Equivalents and Short-Term Investments | 18.67M | 22.13M | 23.00M | 27.89M | 43.66M | 60.73M |
| Total Debt | 0.00 | 0.00 | 0.00 | 485.00K | 295.00K | 86.00K |
| Total Liabilities | 3.60M | 5.38M | 11.56M | 11.17M | 20.35M | 6.80M |
| Stockholders Equity | 64.89M | 66.61M | 61.74M | 67.95M | 108.27M | 55.66M |
Cash Flow | ||||||
| Free Cash Flow | -10.13M | -14.90M | -12.36M | -15.93M | -17.23M | -14.39M |
| Operating Cash Flow | -10.13M | -14.90M | -12.33M | -15.91M | -17.23M | -14.32M |
| Investing Cash Flow | 0.00 | 0.00 | 104.00K | 13.15M | -3.52M | -9.86M |
| Financing Cash Flow | 17.75M | 14.03M | 7.36M | 304.00K | 0.00 | 59.49M |
Grace Therapeutics Technical Analysis
Positive
4.60
Price Trends
4.10
Positive
3.79
Positive
3.45
Positive
Market Momentum
0.03
Negative
57.48
Neutral
76.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Positive. The current price of 4.6 is above the 20-day moving average (MA) of 4.31, above the 50-day MA of 4.10, and above the 200-day MA of 3.45, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 57.48 is Neutral, neither overbought nor oversold. The STOCH value of 76.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRCE.
Grace Therapeutics Risk Analysis
Grace Therapeutics disclosed 51 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grace Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $58.65M | -3.81 | 66.88% | ― | ― | -1.96% | |
56 Neutral | $86.45M | -2.64 | -291.42% | ― | ― | 54.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $36.94M | -1.22 | -28.16% | ― | -44.59% | 93.48% | |
45 Neutral | $14.01M | -1.02 | -333.32% | ― | ― | 23.46% | |
44 Neutral | $32.50M | -4.61 | -10.61% | ― | ― | 70.83% |
* Healthcare Sector Average
GRCE
Grace Therapeutics
2.24
-0.47
-17.34%
PYPD
PolyPid
4.50
1.70
60.71%
ALGS
Aligos Therapeutics
5.99
-0.04
-0.75%
INKT
MiNK Therapeutics
12.20
4.80
64.86%
CVKD
Cadrenal Therapeutics, Inc.
6.67
-9.83
-59.58%
Grace Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
Positive
Apr 27, 2026
On April 27, 2026, Grace Therapeutics updated its corporate presentation, detailing regulatory feedback and development status for its lead programs, particularly GTx-104, a novel intravenous nimodipine designed to address limitations of the long-...
Product-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Receives FDA Complete Response for GTx-104
Negative
Apr 23, 2026
On April 23, 2026, Grace Therapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for GTx-104, an IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage. The FDA c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.